BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 9849454)

  • 1. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
    Flamant F; Rodary C; Rey A; Praquin MT; Sommelet D; Quintana E; Theobald S; Brunat-Mentigny M; Otten J; Voûte PA; Habrand JL; Martelli H; Barrett A; Terrier-Lacombe MJ; Oberlin O
    Eur J Cancer; 1998 Jun; 34(7):1050-62. PubMed ID: 9849454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumors of the orbit: results of the International Society of Pediatric Oncology MMT 84 Study.
    Rousseau P; Flamant F; Quintana E; Voute PA; Gentet JC
    J Clin Oncol; 1994 Mar; 12(3):516-21. PubMed ID: 7509854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
    J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
    Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
    J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
    Stewart RJ; Martelli H; Oberlin O; Rey A; Bouvet N; Spicer RD; Godzinski J; Stevens MC;
    J Clin Oncol; 2003 Mar; 21(5):793-8. PubMed ID: 12610176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee.
    Réguerre Y; Martelli H; Rey A; Rogers T; Gaze M; Ben Arush MW; Devalck C; Oberlin O; Stevens M; Orbach D
    Eur J Cancer; 2012 Sep; 48(13):2020-7. PubMed ID: 22154650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
    Stevens MC; Rey A; Bouvet N; Ellershaw C; Flamant F; Habrand JL; Marsden HB; Martelli H; Sanchez de Toledo J; Spicer RD; Spooner D; Terrier-Lacombe MJ; van Unnik A; Oberlin O
    J Clin Oncol; 2005 Apr; 23(12):2618-28. PubMed ID: 15728225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98.
    McDowell HP; Foot AB; Ellershaw C; Machin D; Giraud C; Bergeron C
    Eur J Cancer; 2010 Jun; 46(9):1588-95. PubMed ID: 20338746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary chemotherapy in the treatment of rhabdomyosarcoma in children: trial of the International Society of Pediatric Oncology (SIOP) preliminary results.
    Flamant F; Rodary C; Voute PA; Otten J
    Radiother Oncol; 1985 Apr; 3(3):227-36. PubMed ID: 3890032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
    Chen C; Shu HK; Goldwein JW; Womer RB; Maity A
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1294-9. PubMed ID: 12654440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
    Bisogno G; Jenney M; Bergeron C; Gallego Melcón S; Ferrari A; Oberlin O; Carli M; Stevens M; Kelsey A; De Paoli A; Gaze MN; Martelli H; Devalck C; Merks JH; Ben-Arush M; Glosli H; Chisholm J; Orbach D; Minard-Colin V; De Salvo GL;
    Lancet Oncol; 2018 Aug; 19(8):1061-1071. PubMed ID: 29941280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma.
    Carli M; Colombatti R; Oberlin O; Stevens M; Masiero L; Frascella E; Koscielniak E; Treuner J; Pinkerton CR
    J Clin Oncol; 1999 Sep; 17(9):2796-803. PubMed ID: 10561355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pediatric rhabdomyosarcoma of the infratemporal fossa].
    Rozan O; Janot F; Oberlin O; Schwaab G; Quintana E; Tran Ba Huy P; Georges B; Luboinski B
    Ann Otolaryngol Chir Cervicofac; 2002 Sep; 119(4):195-201. PubMed ID: 12410115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
    Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
    Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001).
    Abd El-Aal HH; Habib EE; Mishrif MM
    J Egypt Natl Canc Inst; 2006 Mar; 18(1):51-60. PubMed ID: 17237856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal management strategies for rhabdomyosarcoma in children.
    Walterhouse D; Watson A
    Paediatr Drugs; 2007; 9(6):391-400. PubMed ID: 18052409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
    Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
    Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
    Koscielniak E; Jürgens H; Winkler K; Bürger D; Herbst M; Keim M; Bernhard G; Treuner J
    Cancer; 1992 Nov; 70(10):2557-67. PubMed ID: 1482503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conservative approach in localised rhabdomyosarcoma of the bladder and prostate: results from International Society of Paediatric Oncology (SIOP) studies: malignant mesenchymal tumour (MMT) 84, 89 and 95.
    Jenney M; Oberlin O; Audry G; Stevens MC; Rey A; Merks JH; Kelsey A; Gallego S; Haie-Meder C; Martelli H
    Pediatr Blood Cancer; 2014 Feb; 61(2):217-22. PubMed ID: 23997024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.